Ascentage Pharma presented positive Phase Ib trial results at ASCO 2026 for olverembatinib combined with blinatumomab in patients with relapsed or refractory Philadelphia chromosome-positive leukemias, showing high response rates and manageable safety. This novel combination targets difficult-to-treat lymphoid blast phase chronic myeloid leukemia and B-cell precursor acute lymphoblastic leukemia, offering a chemotherapy-free option. Olverembatinib is already approved in China for certain CML cases and is undergoing global Phase III trials, with potential licensing by Takeda for markets outside China. The data supports further development to address unmet needs in aggressive blood cancers.
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
